CNN
—
The US Meals and Drug Administration on Tuesday permitted donanemab, a monoclonal antibody designed to gradual the development of early symptomatic Alzheimer’s illness.
Donanemab, made by Indianapolis-based Eli Lilly, works by serving to the physique take away amyloid plaque buildup within the mind, an indicator of Alzheimer’s illness.
Get CNN Well being’s weekly publication
Lilly stated it is going to be offered below the title Kisunla and would price $695 per vial earlier than insurance coverage, what would quantity to $12,522 for a six-month course or about $32,000 for a 12 months.
This can be a growing story and will likely be up to date.